Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
1°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Allurion Technologies, Inc.
< Previous
1
2
Next >
Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
Today 9:03 EST
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity
February 18, 2025
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Relaunches in France
February 13, 2025
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market
January 24, 2025
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program
January 23, 2025
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity
January 21, 2025
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024
January 14, 2025
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Announces Positive Topline Results From AUDACITY Trial
January 08, 2025
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Technologies, Inc. Announces Reverse Stock Split
December 24, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance
December 02, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program
November 25, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update
November 13, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society’s Annual Conference
November 04, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024
October 30, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon
October 23, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss
October 09, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss
October 01, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Receives Continued Listing Standards Notice from NYSE
September 05, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity
September 05, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors
September 03, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program
August 28, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial
August 20, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Receives Continued Listing Standards Notice from NYSE
August 15, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion to Report Second Quarter 2024 Financial Results on August 13, 2024
July 16, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Announces Pricing of $20 million Public Offering and Concurrent Private Placement
June 28, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Announces Launch of Offering of Common Stock and Warrants
June 26, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight Loss
June 20, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Announces Three Scientific Presentations at the 40th Annual Meeting of the American Society for Metabolic and Bariatric Surgery
June 11, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer
June 05, 2024
From
Allurion Technologies, Inc.
Via
Business Wire
Tickers
ALUR
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.